Hair Mass Spectrometry Imaging of Daily Maraviroc Adherence in HPTN 069/ACTG 5305

Elias Rosen
Eshelman School of Pharmacy, University of North Carolina
Chapel Hill, North Carolina, USA

Presented at virtual CROI 2021
Introduction

Background:

• HPTN 069/ ACTG 5305 assessed safety and tolerability of regimens containing maraviroc (MVC) to prevent HIV Infection in at-risk MSM and women.
• Assessment of adherence included collection of patient hair strands, which can provide long-term measures of drug-taking behavior.

Study Objective:

• To evaluate daily MVC adherence in HPTN 069/ ACTG 5305 hair samples using infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) mass spectrometry imaging (MSI).
Methods

IR-MALDESI MSI

Benchmarking MVC in Hair

HPTN 069/ACTG 5305 Adherence Classification

- MVC was measured in 32 samples from 19 individuals (10 male, 9 female), collected at Week 24, 48, or 49 study visits.
- IR-MALDESI MSI analysis was conducted over the proximal 1cm of hair strands (~1 month of growth).
- Quantitative results were compared to LC-MS/MS results from matched segment lengths.
Results

Benchmarking MVC in Hair

A) MVC Signal Abundance

Weekly Dosing Frequency

B) MVC/Melanin Biomarker

Weekly Dosing Frequency

HPTN 069/ACTG 5305 Adherence Classification

C) MVC/Melanin Biomarker Signal Abundance

Number of Days Prior to Sample Collection

D) $r_s = 0.59$

IR-MALDESI MVC (ng/mg)

LC-MS/MS MVC (ng/mg)

E) MVC/Melanin Biomarker

Days of Adherence in Past Month

Conclusions

• Hair color is an important factor for accurate adherence classification of MVC in hair strands, and likely other antiretrovirals with similar physicochemical properties.

• Normalization of MVC hair strand concentrations by a melanin biomarker increased accuracy of adherence classification relative to MVC alone.

• Daily MVC adherence classification in HPTN 069/ ACTG 5305 hair strands indicated only 8/19 individuals adhered to a daily regimen throughout the prior month.

• IR-MALDESI MSI captures short-term changes in adherence behavior that are incorporated into the long-term accumulation of drug in hair strands.
Acknowledgments

Co-Authors:

Nicole White¹, Mac Gilliland², Monica Gandhi³, Roy Gulick⁴, Angela DM Kashuba¹

¹University of North Carolina at Chapel Hill, Chapel Hill, NC, USA,
²Furman University, Greenville, SC,
³University of California San Francisco, San Francisco, CA, USA,
⁴Weill Cornell Medicine, New York, NY, USA

Funding Sources:

R01AI122319, P30AI050410

HIV Prevention Trials Network (HPTN)

• UM1AI068619-15 (HPTN Leadership and Operations Center), UM1AI068617-15 (HPTN Statistical and Data Management Center), and UM1AI068613-15 (HPTN Laboratory Center).

AIDS Clinical Trials Group (ACTG)

• UM1AI068636-15 (ACTG Leadership and Operations Center), UM1AI068616-15 (ACTG Statistical and Data Management Center), and UM1AI06716-09 (ACTG Laboratory Center).